Journal of Medicinal Chemistry · 2021 · 24 citations · 31 references
PharmacyMedicinal ChemistryOncologyBioorthogonal ChemistryDrug DiscoveryMolecular OncologyCancer ProteomicsProteomic ProfilingCatalytic Site ActivationCatalytic Site ArchitectureCycloaddition ReactionsGlutathione S-transferase ActivityMedicinal Chemistry ApplicationsProteome Reactivity ProfilingProteome-wide Reactivity ProfilingTriple-negative Breast Cancer Therapy
The "inverse drug discovery" strategy is a potent means of exploring the cellular targets of latent electrophiles not typically used in medicinal chemistry. Cyclopropenone, a powerful electrophile, is generally used in bio-orthogonal reactions mediated by triarylphosphine or in photo-triggered cycloaddition reactions. Here, we have studied, for the first time, the proteome reactivity of cyclopropenones in live cells and discovered that the cyclopropenone warhead can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Further structure optimization and signaling pathway validation have led to the discovery of potent inhibitors of GSTP1.
31
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
John K. Eaton, Laura Furst, Richard A. Ruberto et al. · Nature Chemical Biology · 2020 · 472 citations · Full text
D.E. Mortenson, Gabriel J. Brighty, Lars Plate et al. · Journal of the American Chemical Society · 2017 · 305 citations · Full text